In this review, we will consider the mounting evidence that the cellular Abelson tyrosine kinase (c‐Abl) plays a key role in the etiopathogenesis of PD and that inhibition of c‐Abl has the potential to be a disease‐modifying therapy for PD. Here, ABL1 is linked to Parkinson disease.